公开(公告)号：US20230023851A1

公开(公告)日：2023-01-26

申请号：US17362580

申请日：2021-06-29

Applicant: Array BioPharma Inc.

Inventor： Mark Laurence BOYS ,  Bryan Daniel ELLIS ,  John Joseph GAUDINO ,  Erik James HICKEN ,  Ellen Ruth LAIRD ,  Nicholas Charles LAZZARA ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK

IPC: C07D487/04 ,  C07D519/00 ,  A61K45/06

Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20240124474A1

公开(公告)日：2024-04-18

申请号：US18499669

申请日：2023-11-01

Applicant: Array BioPharma Inc.

Inventor： Mark Laurence BOYS ,  Bryan Daniel ELLIS ,  John Joseph GAUDINO ,  Erik James HICKEN ,  Ellen Ruth LAIRD ,  Nicholas Charles LAZZARA ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK

IPC: C07D487/04 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07D519/00

Abstract: This invention relates to compounds of Formula (I):




and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20230041385A1

公开(公告)日：2023-02-09

申请号：US17849621

申请日：2022-06-25

Applicant: Array BioPharma Inc.

Inventor： Bryan Daniel ELLIS ,  Erik James HICKEN ,  Ellen Ruth LAIRD ,  Nicholas Charles LAZZARA ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK ,  Rachel Zoe Rosen ,  Russell Andrew Shelp

IPC: A61K31/519 ,  C07D519/00 ,  C07D471/04 ,  A61K31/551 ,  A61K31/55 ,  A61K31/5386 ,  A61K39/395 ,  A61K31/704 ,  A61K31/337 ,  A61K38/14 ,  A61K31/506 ,  A61K31/502 ,  A61K31/655 ,  A61K31/573 ,  A61K31/7048 ,  A61K31/44

Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20220289721A1

公开(公告)日：2022-09-15

申请号：US17745346

申请日：2022-05-16

Applicant: Array BioPharma Inc.

Inventor： Patrick Michael BARBOUR ,  Katie Keaton BROWN ,  Adam Wade COOK ,  Erik James HICKEN ,  Dean Russell KAHN ,  Ellen Ruth LAIRD ,  Andrew Terrance METCALF ,  David Austin MORENO ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK ,  Brett Joseph PRIGARO ,  Li REN ,  Eugene TARLTON

IPC: C07D403/12 ,  C07D239/90 ,  C07D239/91

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.